Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study (SWITCH‐SEMA 1 study)

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2023-06, Vol.25 (6), p.1503-1511
• Main Authors: Takahashi, Yuka, Nomoto, Hiroshi, Yokoyama, Hiroki, Takano, Yoshinari, Nagai, So, Tsuzuki, Atsushi, Cho, Kyu Yong, Miya, Aika, Kameda, Hiraku, Takeuchi, Jun, Taneda, Shinji, Kurihara, Yoshio, Atsumi, Tatsuya, Nakamura, Akinobu, Miyoshi, Hideaki
• Format: Article
• Language: English
• Subjects: Antidiabetics; Body Weight; clinical trial; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - drug therapy; dulaglutide; GLP‐1 analogue; Glucagon; Glucagon-Like Peptides - adverse effects; Glycated Hemoglobin; Glycemic Control; Hemoglobin; Humans; Hypoglycemic Agents - adverse effects; Immunoglobulin Fc Fragments - adverse effects; liraglutide; Liraglutide - adverse effects; Metabolism; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Questionnaires; Recombinant Fusion Proteins - adverse effects; semaglutide; type 2 diabetes
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14998

Aim To investigate the effects of switching from liraglutide or dulaglutide to once‐weekly semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes. Materials and Methods In this multicentre, open‐labelled, prospective, randomized, parallel‐group comparison study, patients treated with liraglutide 0.9‐1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy. The primary endpoint was the mean change in glycated haemoglobin over 24 weeks. The secondary endpoints included the changes of Diabetes Treatment Satisfaction Questionnaire scores, body weight and metabolic indices. Results In total, 110 patients were enrolled, and 10 were excluded; therefore, 37 patients in plan A and 63 patients in plan B completed the study. Glycated haemoglobin levels were significantly reduced in the semaglutide group in both plans [plan A, 7.8% ± 1.0% to 7.8% ± 0.7% (liraglutide) vs. 7.9% ± 0.7% to 7.3% ± 0.7% (semaglutide), p